United States Hemostats Market Size, Share, and COVID-19 Impact Analysis, By Type (Oxidized Regenerated Cellulose-Based Hemostats, Combination Hemostats, Thrombin-Based Hemostats, and Others), By Formulation (Matrix & Gel Hemostats, Sponge Hemostats, Powder Hemostats, and Others), and United States Hemostats Market Insights, Industry Trend, Forecasts to 2035

United States Hemostats Market Insights Forecasts to 2035

• The US Hemostats Market Size Was Estimated at USD 786.7 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.40% from 2025 to 2035
• The US Hemostats Market Size is Expected to Reach USD 1556.7 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the United States Hemostats Market Size is Anticipated to Reach USD 1556.7 Million by 2035, Growing at a CAGR of 6.40% from 2025 to 2035. The expansion of the United States hemostats market is propelled because it is more necessary to control bleeding during complex surgeries as a result of the rising incidence of chronic illnesses and the volume of surgical procedures.

Market Overview

A hemostat, referred to as an arterial forceps or haemostatic clamp, is a surgical tool that resembles scissors and is used to mechanically compress and clamp blood vessels during medical procedures in order to reduce bleeding. The increased number of surgical procedures conducted in the United States is allowing for the growth of the market. Components that contribute to or support the growth of the market include the increased incidence of injuries and accidents, which also require surgical procedures, and the increased prevalence of chronic diseases requiring surgical intervention. In addition, named companies in the market, including BD, Pfizer Inc., Integra Life Sciences Corporation, Baxter, and Johnson & Johnson Services, Inc., maintain a very large share of the market. The U.S. market is growing as a result of these market participants' increased attention to securing regulatory approvals for the introduction of haemostatic medications. Growth expectations for the market are likely to be affected by the increasing focus of market actors on collaborating with research institutes to complete preclinical and clinical studies for the development and investigation of haemostatic products. With more hospitals and ASCs, the United States' sophisticated healthcare system is able to perform more surgeries. This increases the demand for a range of product options with sufficient capabilities to control bleeding issues during surgical procedures, which in turn increases the number of surgical procedures carried out in the country.

Report Coverage

This research report categorizes the market for the United States hemostats market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States hemostats market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United States hemostats market.

Driving Factors

The growth of the United States hemostats market is boosted because the process of clotting the blood to stop excessive bleeding is facilitated by haemostatic drugs. Since haemostatic devices are critical for achieving hemostasis during surgical procedures, the hemostats industry is directly related to the rise in surgical procedures. The rise in surgical procedures is a part of the rise of hemostat products, which contributes to the growth of operations due to age and chronic diseases. Therefore, there is a noteworthy increase in operations, which led to a corresponding increase in the need for haemostatic products.

Restraining Factors

The United States hemostats market faces obstacles like the fact that the market is at risk because of possible adverse reactions to different hemostatic drugs, which could inhibit market creating complications for patients and worry for healthcare providers.

Market Segmentation

The United States hemostats market share is classified into type and formulation.

• The oxidized regenerated cellulose-based hemostats segment held the largest market share in 2024 and is expected to grow at a remarkable CAGR during the forecast period.

The United States hemostats market is segmented by type into oxidized regenerated cellulose-based hemostats, combination hemostats, thrombin-based hemostats, and others. Among these, the oxidized regenerated cellulose-based hemostats segment held the largest market share in 2024 and is expected to grow at a remarkable CAGR during the forecast period. The segment is driven by their fantastic haemostatic properties that promote clotting and healing in tissue. Other factors that bolster their position in the market are their biocompatibility and biodegradability, and the proven safety record to assist with surgical bleeding.

• The matrix & gel hemostats segment held the highest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

Based on the formulation, the United States hemostats market is segmented into matrix & gel hemostats, sponge hemostats, powder hemostats, and others. Among these, the matrix & gel hemostats segment held the highest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is propelled by the superior functionality and ease-of-use of hemostats, which facilitate various surgical procedures. The product immediately absorbs water from blood and creates a strong mechanical obstruction by utilizing its molecular structure to create a sticky matrix gel.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States hemostats market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Artivion Inc
• Integra Lifesciences Holdings Corp
• Pfizer Inc
• Stryker Corp
• Becton Dickinson & Co
• Baxter International Inc
• Johnson & Johnson
• Integra LifeSciences
• BD
• Others

Recent Development

• In January 2023, LifeGel Absorbable Surgical Hemostat, developed by Medcura, Inc., received the U.S. FDA’s Breakthrough Device Designation. This is the only product with this designation and can be used in surgical procedures where swelling cannot be tolerated.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United States hemostats market based on the following segments:

United States Hemostats Market, By Type

• Oxidized Regenerated Cellulose-Based Hemostats
• Combination Hemostats
• Thrombin-Based Hemostats
• Others

United States Hemostats Market, By Formulation

• Matrix & Gel Hemostats
• Sponge Hemostats
• Powder Hemostats
• Others